Angiotensin-II receptor antibody - Materia Medica Holding

Drug Profile

Angiotensin-II receptor antibody - Materia Medica Holding

Alternative Names: Cardosten

Latest Information Update: 16 Sep 2011

Price : $50

At a glance

  • Originator Materia Medica Holding Research and Production Company
  • Class Antibodies; Heart failure therapies
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Clinical Phase Unknown Heart failure

Most Recent Events

  • 31 Aug 2011 Clinical trials in Heart failure in Russia (PO)
  • 31 Aug 2011 Efficacy data from a Clinical trial in Heart failure released by Materia Medica Holding Research and Production Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top